Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience.
The following review of iron(III)-hydroxide polymaltose complex (IPC, Maltofer) shows that iron is significantly bioavailable after oral administration, especially in iron-deficient subjects. Numerous clinical trials in men, women, children and infants have shown that IPC is effective in treating iron deficiency anaemia (IDA). Due to its kinetic properties, IPC is best given with meals, and probably in an iron dose slightly higher than that of the classical iron salts. In terms of acceptance and patient compliance, IPC presents a clear advantage over ferrous salts. Many studies have shown a lower rate of treatment interruption with IPC than with ferrous salts. This is usually associated with a lower incidence of adverse events related to the upper gastro intestinal tract.
Geisser
Peter
P
Vifor (International) Inc., St. Gallen, Switzerland. peter.geisser@vifor.com
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D019587:Dietary Supplements; D004347:Drug Interactions; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005296:Ferrous Compounds / Q000009:adverse effects / Q000627:therapeutic use; D005492:Folic Acid / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007223:Infant; D008297:Male; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic
D005290:Ferric Compounds; D005296:Ferrous Compounds; D006454:Hemoglobins; D005492:Folic Acid; C013276:teferrol